Advanced search
Publication Cover
Oncolytic Virotherapy Volume 3, 2014 - Issue
Journal homepage
189
Views
66
CrossRef citations to date
0
Altmetric
Review

Applications of coxsackievirus A21 in oncology

Stephen Bradley1 Leeds Institute of Cancer and Pathology, Cancer Research UK and Experimental Cancer Medicine Centre, St James’ University Hospital, Leeds, UK
,
Adam D Jakes1 Leeds Institute of Cancer and Pathology, Cancer Research UK and Experimental Cancer Medicine Centre, St James’ University Hospital, Leeds, UK
,
Kevin Harrington2 Division of Cancer Biology, The Institute of Cancer Research, London, UK
,
Hardev Pandha3 Oncology Department, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
,
Alan Melcher1 Leeds Institute of Cancer and Pathology, Cancer Research UK and Experimental Cancer Medicine Centre, St James’ University Hospital, Leeds, UK
&
Fiona Errington-Mais1 Leeds Institute of Cancer and Pathology, Cancer Research UK and Experimental Cancer Medicine Centre, St James’ University Hospital, Leeds, UKCorrespondence[email protected]
Pages 47-55 | Published online: 10 Apr 2014

Citations (66)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Danielle K. DePalo, Ahmad Tarhini & Jonathan S. Zager. (2022) The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs 31:1, pages 95-104.
Read now
Ayesha Sarwar, Laila Hashim, Muhammad Salman Faisal, Mobeen Zaka Haider, Zahoor Ahmed, Tehniat Faraz Ahmed, Moazzam Shahzad, Iqraa Ansar, Sundas Ali, Muhammad Muaaz Aslam & Faiz Anwer. (2021) Advances in viral oncolytics for treatment of multiple myeloma – a focused review. Expert Review of Hematology 14:12, pages 1071-1083.
Read now
Nadishka Jayawardena, John T Poirier, Laura N Burga & Mihnea Bostina. (2020) Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development. Oncolytic Virotherapy 9, pages 1-15.
Read now
Matthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, Shane Foo, Eva Crespo-Rodriguez, Galabina Bozhanova, Emmanuel Christian Patin, Martin McLaughlin, David Mansfield, Gabriella Baker, Lorna Grove, Malin Pedersen, Joan Kyula, Victoria Roulstone, Anna Wilkins, Fiona McDonald, Kevin Harrington & Alan Melcher. (2020) Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy 20:6, pages 635-652.
Read now
Sergei S Zainutdinov, Galina V Kochneva, Sergei V Netesov, Peter M Chumakov & Olga V Matveeva. (2019) Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. Oncolytic Virotherapy 8, pages 9-26.
Read now
Kenneth Lundstrom. (2018) New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics: Targets and Therapy 12, pages 43-60.
Read now

Articles from other publishers (60)

Matthew Holmes, Gina B. Scott, Samuel Heaton, Tyler Barr, Basem Askar, Louise M.E. Müller, Victoria A. Jennings, Christy Ralph, Cathy Burton, Alan Melcher, Peter Hillmen, Christopher Parrish & Fiona Errington-Mais. (2023) Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. Molecular Therapy - Oncolytics 29, pages 17-29.
Crossref
Miranda Sam, Mohammed Selman, Weilong Zhao, Jiwon Jung, Aarron Willingham, Uyen Phan, Gary C. Starling & Qinshan Gao. (2023) Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome. Journal of Virology 97:5.
Crossref
Agnija Rasa & Pēteris Alberts. (2022) Oncolytic virus preclinical toxicology studies. Journal of Applied Toxicology 43:5, pages 620-648.
Crossref
Akira Sakamoto, Hiroyuki Inoue, Shohei Miyamoto, Shun Ito, Yasushi Soda & Kenzaburo Tani. (2023) Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Scientific Reports 13:1.
Crossref
Kenneth Lundstrom. (2023) Gene Therapy Cargoes Based on Viral Vector Delivery. Current Gene Therapy 23:2, pages 111-134.
Crossref
Christianne Groeneveldt, Jasper van den Ende & Nadine van Montfoort. (2023) Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?. Cytokine & Growth Factor Reviews 70, pages 1-12.
Crossref
Kenneth Lundstrom. (2023) Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses 15:3, pages 698.
Crossref
Velia Penza, Justin W. Maroun, Rebecca A. Nace, Autumn J. Schulze & Stephen J. Russell. (2023) Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model. Molecular Therapy - Oncolytics 28, pages 15-30.
Crossref
Danielle K. DePalo & Jonathan S. Zager. (2023) Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers 15:5, pages 1404.
Crossref
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman & Sumati Gupta. (2023) Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer 11:1, pages e005007.
Crossref
Paul F. Gillespie, Richard R. RustandiAndrew R. SwartzLiang ShangJessica RaffaeleAshley ProutNicholas CunninghamMohamed DawodJames Z. Deng, Shiyi WangJessica OlsonYvonne ShiehJohn W. Loughney. (2023) Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western. Human Gene Therapy 34:1-2, pages 68-77.
Crossref
Henglong Hu, Qidong Xia, Jia Hu & Shaogang Wang. (2022) Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. Journal of Clinical Medicine 11:23, pages 6997.
Crossref
Aleksandar Antanasijevic, Autumn J Schulze, Vijay S Reddy & Andrew B Ward. (2022) High-resolution structural analysis of enterovirus-reactive polyclonal antibodies in complex with whole virions. PNAS Nexus 1:5.
Crossref
Wouter Johannes Petrus van den Braak, Bella Monica, Diana Limpens, Dedeke Rockx-Brouwer, Matthijn de Boer & Dinja Oosterhoff. (2022) Construction of a Vero Cell Line Expressing Human ICAM1 for the Development of Rhinovirus Vaccines. Viruses 14:10, pages 2235.
Crossref
Andrew R. Swartz, Yvonne Shieh, Amanda Gulasarian, Jessica W. Olson & Richard R. Rustandi. (2022) Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection. Virology 573, pages 167-175.
Crossref
Spyridon Konstantinidis, Murphy R. Poplyk, Andrew R. Swartz, Richard R. Rustandi, Rachel Thompson & Sheng-Ching Wang. (2022) Application of cation exchange chromatography in bind and elute and flowthrough mode for the purification of enteroviruses. Journal of Chromatography A 1676, pages 463259.
Crossref
Florentia Dimitriou, Axel Hauschild, Janice M. Mehnert & Georgina V. Long. (2022) Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book:42, pages 745-766.
Crossref
James Z. Deng, Richard R. RustandiDamon BarbacciAndrew R. SwartzAmanda GulasarianJohn W. Loughney. (2022) Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification. Human Gene Therapy 33:13-14, pages 765-775.
Crossref
James Z. Deng, Richard R. Rustandi, Andrew Swartz, Yvonne Shieh, Jack B. Baker, Josef Vlasak, Shiyi Wang & John W. Loughney. (2022) SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus. Molecular Therapy - Oncolytics 24, pages 139-147.
Crossref
Nasser Hashemi Goradel, Arezoo Alizadeh, Shahnaz Hosseinzadeh, Mitra Taghipour, Zeinab Ghesmati, Arash Arashkia & Babak Negahdari. (2022) Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Future Oncology 18:2, pages 245-259.
Crossref
Kenneth Lundstrom. 2022. The Biological Role of a Virus. The Biological Role of a Virus 285 341 .
Kenneth Lundstrom. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 28 .
Robert H. I. Andtbacka, Brendan Curti, Gregory A. Daniels, Sigrun Hallmeyer, Eric D. Whitman, Jose Lutzky, Lynn E. Spitler, Karl Zhou, Praveen K. Bommareddy, Mark Grose, Meihua Wang, Cai Wu & Howard L. Kaufman. (2021) Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. Journal of Clinical Oncology 39:34, pages 3829-3838.
Crossref
Johannes P. W. Heidbuechel & Christine E. Engeland. (2021) Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. Journal of Hematology & Oncology 14:1.
Crossref
William J. Burnett, David M. Burnett, Gennie Parkman, Andrew Ramstead, Nico Contreras, William Gravley, Sheri L. Holmen, Matthew A. Williams & Matthew W. VanBrocklin. (2021) Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers 13:17, pages 4462.
Crossref
Ali Ahmadi, Hadi E.G. Ghaleh, Ruhollah Dorostkar, Mahdieh Farzanehpour & Masoumeh Bolandian. (2021) Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review. Current Cancer Therapy Reviews 17:3, pages 173-178.
Crossref
Gang Cheng, Hui Dong, Chen Yang, Yang Liu, Yi Wu, Lifen Zhu, Xiangmin Tong & Shibing Wang. (2021) A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell International 21:1.
Crossref
Alexander Malogolovkin, Nizami Gasanov, Alexander Egorov, Marianna Weener, Roman Ivanov & Alexander Karabelsky. (2021) Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Viruses 13:7, pages 1271.
Crossref
Huitao Liu & Honglin Luo. (2021) Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges. Viruses 13:6, pages 1082.
Crossref
Anja Geisler, Ahmet Hazini, Lisanne Heimann, Jens Kurreck & Henry Fechner. (2021) Coxsackievirus B3—Its Potential as an Oncolytic Virus. Viruses 13:5, pages 718.
Crossref
Valentina Marchica, Federica Costa, Gaetano Donofrio & Nicola Giuliani. (2021) Oncolytic Virotherapy and Microenvironment in Multiple Myeloma. International Journal of Molecular Sciences 22:5, pages 2259.
Crossref
Nasser Hashemi Goradel, Alexander T. Baker, Arash Arashkia, Nasim Ebrahimi, Sajjad Ghorghanlu & Babak Negahdari. (2021) Oncolytic virotherapy: Challenges and solutions. Current Problems in Cancer 45:1, pages 100639.
Crossref
Ivan Y. Filin, Valeriya V. Solovyeva, Kristina V. Kitaeva, Catrin S. Rutland & Albert A. Rizvanov. (2020) Current Trends in Cancer Immunotherapy. Biomedicines 8:12, pages 621.
Crossref
Rebecca Burchett, Scott Walsh, Yonghong Wan & Jonathan L. Bramson. (2020) A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy. Cytokine & Growth Factor Reviews 56, pages 149-159.
Crossref
Vera Kemp, Martine L.M. Lamfers, Gabri van der Pluijm, Bernadette G. van den Hoogen & Rob C. Hoeben. (2020) Developing oncolytic viruses for clinical use: A consortium approach. Cytokine & Growth Factor Reviews 56, pages 133-140.
Crossref
Kenneth Lundstrom. (2020) Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 12:11, pages 1324.
Crossref
June Kyu Hwang, JinWoo Hong & Chae-Ok Yun. (2020) Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. International Journal of Molecular Sciences 21:22, pages 8627.
Crossref
Chang-Myung Oh, Hong Jae Chon & Chan Kim. (2020) Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences 21:20, pages 7743.
Crossref
Mark R. Middleton, Christoph Hoeller, Olivier Michielin, Caroline Robert, Caroline Caramella, Katarina Öhrling & Axel Hauschild. (2020) Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. British Journal of Cancer 123:6, pages 885-897.
Crossref
Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang & Lu Lu. (2020) Development of oncolytic virotherapy: from genetic modification to combination therapy. Frontiers of Medicine 14:2, pages 160-184.
Crossref
Altijana Hromic-Jahjefendic & Kenneth Lundstrom. (2020) Viral Vector-Based Melanoma Gene Therapy. Biomedicines 8:3, pages 60.
Crossref
Yuhui Zhang & Zhuoming Liu. (2020) Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. Current Pharmaceutical Design 25:40, pages 4251-4263.
Crossref
Autumn J. Schulze. 2020. Oncolytic Viruses. Oncolytic Viruses 77 94 .
Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson, Kevin J. Harrington, Hardev Pandha, Christy Ralph, Richard J. Kelly, Gordon Cook, Alan A. Melcher & Fiona Errington-Mais. (2019) Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Brie M. Chun, David B. Page & Heather L. McArthur. (2019) Combination Immunotherapy Strategies in Breast Cancer. Current Breast Cancer Reports 11:4, pages 228-240.
Crossref
Venkatesh Sivanandam, Christopher J. LaRocca, Nanhai G. Chen, Yuman Fong & Susanne G. Warner. (2019) Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. Molecular Therapy - Oncolytics 13, pages 93-106.
Crossref
Cormac McCarthy, Nadishka Jayawardena, Laura N. Burga & Mihnea Bostina. (2019) Developing Picornaviruses for Cancer Therapy. Cancers 11:5, pages 685.
Crossref
Kenneth Lundstrom. (2019) Gene Therapy Today and Tomorrow. Diseases 7:2, pages 37.
Crossref
Kenneth Lundstrom. (2019) RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes 10:3, pages 189.
Crossref
Juliana F. Germano, Savannah Sawaged, Hannaneh Saadaeijahromi, Allen M. Andres, Ralph Feuer, Roberta A. Gottlieb & Jon Sin. (2019) Coxsackievirus B infection induces the extracellular release of miR-590-5p, a proviral microRNA. Virology 529, pages 169-176.
Crossref
David Liu, Russell W. Jenkins & Ryan J. Sullivan. (2018) Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology 20:1, pages 41-54.
Crossref
Adam Ajina & John Maher. 2019. Cancer Immunotherapy. Cancer Immunotherapy 217 292 .
Christopher J. LaRocca & Susanne G. Warner. (2018) Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clinical and Translational Medicine 7:1.
Crossref
Nadishka JayawardenaLaura N. BurgaRichard A. EasingwoodYoshimasa Takizawa, Matthias Wolf & Mihnea Bostina. (2018) Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus. Proceedings of the National Academy of Sciences 115:46.
Crossref
Ibrahim Eissa, Itzel Bustos-Villalobos, Toru Ichinose, Shigeru Matsumura, Yoshinori Naoe, Noriyuki Miyajima, Daishi Morimoto, Nobuaki Mukoyama, Wu Zhiwen, Maki Tanaka, Hitoki Hasegawa, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera & Hideki Kasuya. (2018) The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers 10:10, pages 356.
Crossref
Nikolas Tim Martin & John Cameron Bell. (2018) Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy 26:6, pages 1414-1422.
Crossref
Kenneth Lundstrom. (2018) Viral Vectors in Gene Therapy. Diseases 6:2, pages 42.
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Adam Ajina & John Maher. (2017) Prospects for combined use of oncolytic viruses and CAR T-cells. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Zahid Delwar, Kaixin Zhang, Paul S. Rennie & William Jia. (2016) Oncolytic virotherapy for urological cancers. Nature Reviews Urology 13:6, pages 334-352.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.